The Trinity Stack
Testosterone + Growth Hormone + Retatrutide
Brain-first body recomposition. The rationale for combining three compounds — and where the evidence stops.
🧠 The Brain-First Paradigm
Most people think of GLP-1 agonists as weight-loss drugs. The emerging science suggests these compounds also act directly on the brain, not only on body weight.
GLP-1 receptors are densely expressed in the hippocampus, prefrontal cortex, and hypothalamus — regions governing memory consolidation, executive function, and metabolic regulation, respectively.[1] GLP-1 drugs act on these circuits to reduce appetite; whether cognitive effects in humans come before body-composition changes has not been established.
Human evidence is early: a small open-label pilot (n=19) of liraglutide in people with mood disorders found improved objective cognitive test scores after 4 weeks, with no placebo group.[2] Controlled trials are needed.
Four Proposed Brain Pathways (mostly preclinical)
In rats, central GLP-1 receptor stimulation altered amygdala serotonin signaling: acute dosing increased anxiety-like behavior, while chronic dosing reduced depression-like behavior.[3]
In rodents, brain GLP-1 receptors support learning and protect hippocampal neurons from injury.[4]
Brain insulin resistance has been linked to type 2 diabetes and Alzheimer's disease; whether GLP-1 drugs improve brain glucose use in humans is not established.[5]
In mouse models of Parkinson's disease, a different GLP-1 receptor agonist (NLY01) blocked microglia-driven conversion of astrocytes to a neurotoxic state.[6]
The Trinity Stack is built around this proposed brain-first rationale, pairing retatrutide with testosterone and growth hormone, which also have central nervous system effects in animal and small human studies. The combination itself has not been studied.
🔬 The Three Components
Testosterone is the foundational androgen in the Trinity Stack. Beyond its well-documented role in muscle protein synthesis and body composition, testosterone also acts on the central nervous system.
Brain Mechanisms
Testosterone acts on the brain in rodent and some human studies, but a review of this research describes the behavioral findings as controversial, with results varying by dose, timing, and route.[7]
In 25 healthy older men, 6 weeks of testosterone improved some spatial and verbal memory measures.[8]
In healthy older men, 3 months of testosterone supplementation improved spatial cognition but no other cognitive domain; the authors suggest the effect likely runs through conversion to estrogen.[9]
A meta-analysis pooled placebo-controlled trials of testosterone treatment in patients already diagnosed with depression; it did not assess whether low testosterone raises depression risk.[10]
Body recomp role: In this stack, testosterone is the muscle-support component; in older men it increased muscle protein synthesis and strength.[20] Its effect during a GLP-1-driven caloric deficit has not been tested.
Testosterone is FDA-approved for the treatment of hypogonadism (low testosterone). Multiple delivery methods are approved: injectable cypionate/enanthate, topical gels, and subcutaneous pellets. Testosterone is a Schedule III controlled substance in the United States.
Human growth hormone drives tissue repair, metabolic regulation, and cellular regeneration. In the Trinity Stack, its most overlooked role is neurological.
Brain Mechanisms
In adult rats, peripheral IGF-I infusion increased hippocampal neurogenesis; GH acts largely through IGF-1.[11]
In rodents, circulating IGF-I mediates the protective effects of exercise against brain injury.[12]
GH is released primarily during slow-wave sleep (SWS). In healthy men, age-related declines in slow-wave sleep were accompanied by declines in GH secretion.[13]
GH-stimulated hepatic IGF-1 crosses the blood-brain barrier and activates PI3K/Akt survival signaling in neurons, promoting cell survival and reducing apoptosis under metabolic stress.[14]
Body recomp role: In this stack, GH is the fat-metabolism component; it stimulates lipolysis, and its protein-sparing effect is described mainly during fasting and other catabolic states.[21] Its effect on body composition during a GLP-1-driven caloric deficit has not been tested.
Recombinant human GH (somatropin) is FDA-approved for adult GH deficiency and several pediatric conditions. Use for anti-aging or body composition is not an approved indication, and under US federal law (21 U.S.C. § 333(e)) distributing GH for such non-approved uses is specifically prohibited. GH is not a controlled substance but requires a prescription.
Retatrutide (LY3437943) is a novel tri-agonist peptide activating three incretin-related receptors simultaneously: GLP-1, GIP, and glucagon. It adds GIP and glucagon receptor activity to GLP-1 agonism; no head-to-head trial against semaglutide has been published.
In the Phase 2 trial published in the New England Journal of Medicine, the 12 mg retatrutide group achieved a mean body weight reduction of 24.2% at 48 weeks.[15] In the Phase 3 TRIUMPH-1 trial (2,339 adults with obesity without diabetes, published in the New England Journal of Medicine in September 2026), the mean change in body weight at 80 weeks was −23.7% at 9 mg and −25.0% at 12 mg, vs −3.9% with placebo.[23]
Brain Mechanisms
Retatrutide activates GLP-1, GIP, and glucagon receptors; whether it acts on all three in the human brain has not been studied. In adult rats, GIP and its receptor are expressed in the hippocampus, and GIP induced proliferation of hippocampal progenitor cells.[16]
In fasted rats, GLP-1 injected into the brain inhibited feeding and activated neurons in the hypothalamic paraventricular nucleus and the amygdala, pointing to a central role for GLP-1 in satiety.[17]
The glucagon component adds hepatic and energy-expenditure effects to GLP-1 agonism; whether it changes central metabolic set points in humans is unknown.[18]
Body recomp role: In this stack, retatrutide is the appetite-reduction component. Whether adding testosterone and GH changes lean-mass retention on retatrutide has not been tested.
As of October 2026, retatrutide has not received FDA approval. Its Phase 3 TRIUMPH-1 (NCT05929066) and TRIUMPH-2 (NCT05929079) trials are listed as completed on ClinicalTrials.gov, and TRIUMPH-1 was published in the New England Journal of Medicine in September 2026.[23] It is manufactured by Eli Lilly. All data referenced here comes from published trial results. Availability through research chemical suppliers does not constitute regulatory approval.
🔄 The Synergy Matrix
The rationale is that each compound complements the other two. These interactions are theoretical — no trial has tested the combination.
In a small crossover study of seven healthy men aged 60–77, supraphysiologic testosterone raised fasting GH and IGF-1 and increased basal and pulsatile GH secretion.[19]
GH secretion is closely tied to slow-wave sleep.[13] Whether GH therapy improves sleep or testosterone production has not been established.
Hypothesis: weight loss on retatrutide could change how tissues respond to testosterone and GH. No study has tested this.
Hypothesis: effects of testosterone on mood or motivation could affect adherence. No study has measured this, and the human evidence on testosterone and behavior is mixed.[7]
Hypothesis: GH effects on tissue repair could support recovery from training. Whether GH therapy improves recovery or sleep in this context has not been established.
The intended division of labor: retatrutide reduces appetite, testosterone supports muscle, GH supports fat mobilization. Whether the combination improves body composition beyond retatrutide alone is unknown.
💪 Body Recomposition
The stack's rationale is that each compound addresses a different part of fat loss and muscle preservation. The combination has not been tested in a trial.
True body recomposition (losing fat while maintaining or gaining lean mass) is difficult because a caloric deficit inherently threatens muscle tissue. The Trinity Stack addresses this through division of labor:
In six healthy older men with low-normal testosterone, 4 weeks of testosterone increased muscle protein synthesis and strength, possibly via the intramuscular IGF-I system. The study did not include a caloric deficit.[20]
Stimulates hormone-sensitive lipase in adipocytes, prioritizing visceral fat oxidation. GH shifts the fuel substrate from glucose to fatty acids, sparing muscle glycogen and protein.[21]
Reduces appetite and food intake through central pathways; the glucagon component is thought to increase energy expenditure.
The intended effect: energy balance shifts negative (retatrutide) while testosterone and GH are meant to protect muscle and favor fat loss. This combined outcome has not been measured in a trial.
In the Phase 2 retatrutide trial, the 12 mg group lost a mean 24.2% of body weight at 48 weeks;[15] in Phase 3 TRIUMPH-1, the 12 mg group's mean change was −25.0% at 80 weeks.[23] Controlled studies of the full Trinity Stack combination have not been published, so whether adding testosterone and GH changes lean-mass retention on retatrutide is unknown.
📈 Cognitive Enhancement Timeline
What users and practitioners describe, week by week. Unless a citation is shown, these are anecdotal reports, not trial findings.
Some users report mood and sleep changes in the first weeks. These are anecdotal reports, not trial findings.
Cognitive effects in humans are not established. A small open-label liraglutide pilot reported improved cognitive test scores at 4 weeks.[2]
Body composition changes may start becoming visible as weight loss accumulates. Neurogenesis findings for IGF-1 come from rodent studies and have not been shown in humans.
In the Phase 2 retatrutide trial, weight loss continued through 48 weeks.[15] Long-term effects of the full combination on cognition, sleep, or body composition are unknown.
This timeline represents a synthesis of published clinical trial data for individual compounds and practitioner reports. No controlled trial has studied the three-compound combination together. Individual responses vary based on baseline health, dosing, genetics, and lifestyle factors.
📋 Protocol Overview
Ranges commonly described for each compound individually — not tested together in any trial. This is not medical advice — all protocols should be designed and monitored by a qualified physician.
| Compound | Typical Range | Frequency | Administration |
|---|---|---|---|
| Testosterone Cypionate | Set by prescriber | Per prescription | Intramuscular or subcutaneous injection |
| Growth Hormone | Set by prescriber | Per prescription | Subcutaneous injection, fasted or before bed |
| Retatrutide | Titrated up to target dose | 1x/week | Subcutaneous injection |
Timing Considerations
Injection frequency and timing are set by the prescriber; some protocols split the weekly dose into two injections.
Timing is set by the prescriber. Morning and pre-bed dosing are both described; GH is naturally released mainly during slow-wave sleep.[13]
Once-weekly injection, same day each week. In trials, doses were escalated stepwise from a lower starting dose to reduce GI side effects.
Retatrutide is not approved, so there is no labeled titration schedule. Trials used stepwise dose escalation; nausea and other GI effects are the most commonly reported side effects of GLP-1 agonists.
All three compounds require physician oversight. Testosterone is a controlled substance requiring a prescription. Growth hormone requires proper diagnosis and prescription. Retatrutide is an investigational compound not yet approved for clinical use. Never self-prescribe or self-administer without medical guidance.
🩺 Monitoring & Safety
Any multi-compound protocol needs close monitoring. These are commonly monitored blood markers and safety considerations; the frequencies shown are illustrative only, and the actual testing schedule and thresholds should be set by your physician.
Essential Blood Markers
| Marker | Why It Matters | Frequency |
|---|---|---|
| Total & Free Testosterone | Confirm therapeutic levels; avoid supraphysiologic exposure | Baseline, 6 weeks, then quarterly |
| Estradiol (E2) | Testosterone aromatizes to estrogen; monitor for gynecomastia risk | With testosterone draws |
| IGF-1 | Primary biomarker of GH activity; target age-adjusted normal range | Baseline, 4 weeks, then quarterly |
| HbA1c & Fasting Glucose | GH can impair insulin sensitivity — monitor glucose control throughout | Baseline, then quarterly |
| Lipid Panel | Testosterone can alter HDL/LDL ratios; GLP-1 agonists generally improve lipids | Baseline, then quarterly |
| CBC (Complete Blood Count) | Testosterone stimulates erythropoiesis; monitor hematocrit to prevent polycythemia | Baseline, 6 weeks, then quarterly |
| PSA | Prostate-specific antigen; standard monitoring during TRT (men over 40) | Annual |
| Liver & Kidney Function | ALT, AST, creatinine, BUN — general metabolic safety | Baseline, then quarterly |
| Thyroid Panel (TSH, Free T3/T4) | GH can affect thyroid hormone conversion; monitor for hypothyroid symptoms | Baseline, then semi-annually |
Known Side Effects by Compound
Acne, hair thinning (DHT-mediated), polycythemia (elevated hematocrit), mood changes, testicular atrophy (endogenous production suppression), potential fertility impact. Estrogen-related: water retention, gynecomastia.
Joint pain, carpal tunnel syndrome (fluid retention), potential insulin resistance, edema, headache. A UK cohort study examined cancer risk in patients treated with pituitary-derived human GH in 1959–85;[22] long-term cancer risk of supraphysiologic GH use in adults has not been established.
Gastrointestinal events were the most common adverse events in the Phase 2 trial; they were dose-related, mostly mild to moderate, and partly mitigated by a lower starting dose.[15]
GH can antagonize insulin sensitivity — monitor glucose carefully. Testosterone-driven erythrocytosis may compound with any dehydration from GLP-1-related appetite suppression. Hydration is critical.
Severe abdominal pain (pancreatitis risk), markedly elevated hematocrit (stroke/clot risk), chest pain, sudden severe headache, vision changes, signs of thyroid dysfunction. Do not adjust compounds without physician guidance if any of these occur.
📌 Key Takeaways
✅ What We Know
- GLP-1 receptor agonists show neuroprotective and cognitive effects mainly in preclinical studies; human evidence is limited to small pilots
- Retatrutide: −25.0% mean body weight change at 12 mg over 80 weeks in Phase 3 TRIUMPH-1 (NEJM 2026), after 24.2% at 48 weeks in Phase 2
- In small trials of healthy older men, testosterone supplementation improved some spatial or memory measures but not others
- GH secretion is closely tied to slow-wave sleep
- Testosterone and GH are FDA-approved for specific deficiency conditions; retatrutide is investigational
⚠️ What We Don't Know
- No controlled trial has studied the three-compound Trinity Stack combination together
- Retatrutide safety beyond the 80-week Phase 3 period, and its eventual FDA label, are not yet established
- No dosing for the combination has been tested in a trial
- Individual genetic variation may significantly affect response profiles
- Interaction effects between GH-induced insulin resistance and retatrutide need more study
- Whether cognitive benefits persist after discontinuation is unknown
- Retatrutide is not FDA-approved and its final safety/efficacy profile is not yet established
🛒 Recommended Supplies
Home-monitoring tools for the markers in the Monitoring & Safety section, plus reconstitution water. All links support HighPeptides through affiliate partnerships.
Finger-prick or saliva kit, lab-processed — total/free testosterone on the marker list above
Order this lab test at HealthLabs → Shop on Amazon →Meter, strips and lancets for checking fasting glucose at home
Shop on Amazon →Automatic cuff monitor with reading memory for home logging
Shop on Amazon →Sterile reconstitution water for peptide preparation
Shop at Swiss Chems →Supplies You'll Need
Practical, low-cost supplies for safe reconstitution, measuring, and storage. These are Amazon affiliate links.
- GLUCO-CARE Insulin Syringes 31G, 1 mL, 5/16" (100-count) →
31G × 5/16" 1 mL — the standard configuration for subcutaneous research dosing; single-use only.
- Curad Sterile Alcohol Prep Pads, 70% Isopropyl (400-count) →
Individually wrapped 70% isopropyl pads — one for the vial septum and one for the site, every time.
- Oakridge Sharps Container, 1-Quart (3-pack) →
Used needles go in a sharps container, never household trash — a 1-quart 3-pack covers months of research.
- Ks-Tek Sterile 10 mL Vials with Self-Healing Injection Port →
Steam-sterilized empty vials with self-healing septa — for holding reconstituted solutions between draws.
- Moyite 9-Slot Vial Holder for Refrigerator (fits 5–10 mL vials) →
Keeps reconstituted vials upright and organized in the fridge — fits standard-height 5–10 mL vials.
As an Amazon Associate, HighPeptides earns from qualifying purchases.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide — $19 (normally $29) →
New to peptides? Start with the $19 Buyer’s Playbook →
HighPeptides earns a commission on purchases. Lab-test standing and regulatory notices for every vendor we track, including this one, are on our vendors page.
References
- Hölscher C. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J Endocrinol. 2014;221(1):T31-T41. doi:10.1530/JOE-13-0221
- Mansur RB, et al. Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study. J Affect Disord. 2017;207:114-120. doi:10.1016/j.jad.2016.09.056
- Anderberg RH, et al. GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. Psychoneuroendocrinology. 2016;65:54-66. doi:10.1016/j.psyneuen.2015.11.021
- During MJ, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003;9(9):1173-1179. doi:10.1038/nm919
- Arnold SE, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol. 2018;14(3):168-181. doi:10.1038/nrneurol.2017.185
- Yun SP, et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. Nat Med. 2018;24(7):931-938. doi:10.1038/s41591-018-0051-5
- Celec P, et al. On the effects of testosterone on brain behavioral functions. Front Neurosci. 2015;9:12. doi:10.3389/fnins.2015.00012
- Cherrier MM, et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology. 2001;57(1):80-88. doi:10.1212/wnl.57.1.80
- Janowsky JS, et al. Testosterone influences spatial cognition in older men. Behav Neurosci. 1994;108(2):325-332. doi:10.1037/0735-7044.108.2.325
- Zarrouf FA, et al. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract. 2009;15(4):289-305. doi:10.1097/01.pra.0000358315.88931.fc
- Åberg MA, Åberg ND, et al. Peripheral infusion of IGF-I selectively induces neurogenesis in the adult rat hippocampus. J Neurosci. 2000;20(8):2896-2903. doi:10.1523/JNEUROSCI.20-08-02896.2000
- Carro E, Trejo JL, et al. Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy. J Neurosci. 2001;21(15):5678-5684. doi:10.1523/JNEUROSCI.21-15-05678.2001
- Van Cauter E, et al. Age-related changes in slow wave sleep and REM sleep and relationship with growth hormone and cortisol levels in healthy men. JAMA. 2000;284(7):861-868. doi:10.1001/jama.284.7.861
- Fernandez AM, Torres-Alemán I. The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci. 2012;13(4):225-239. doi:10.1038/nrn3209
- Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
- Nyberg J, et al. Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation. J Neurosci. 2005;25(7):1816-1825. doi:10.1523/JNEUROSCI.4920-04.2005
- Turton MD, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379(6560):69-72. doi:10.1038/379069a0
- Müller TD, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. doi:10.1016/j.molmet.2019.09.010
- Veldhuis JD, Keenan DM, Mielke K, Miles JM, Bowers CY. Testosterone supplementation in healthy older men drives GH and IGF-I secretion without potentiating peptidyl secretagogue efficacy. Eur J Endocrinol. 2005;153(4):577-586. doi:10.1530/eje.1.02001. PMID: 16189179
- Urban RJ, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol. 1995;269(5):E820-E826. doi:10.1152/ajpendo.1995.269.5.E820
- Møller N, Jørgensen JOL. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30(2):152-177. doi:10.1210/er.2008-0027
- Swerdlow AJ, et al. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet. 2002;360(9329):273-277. doi:10.1016/S0140-6736(02)09519-3
- Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. N Engl J Med. 2026 Sep 29. doi:10.1056/NEJMoa2604169. PMID: 42814954